N@N

Chris Shibutani Initiated (SNDX) at Strong Buy and Held Target at $30 on, Oct 11th, 2023

Chris Shibutani of Goldman Sachs, Initiated "Syndax Pharmaceuticals, Inc." (SNDX) at Strong Buy and Held Target at $30 on, Oct 11th, 2023.

Chris has made no other calls on SNDX in the last 4 months.

There are 9 other peers that have a rating on SNDX. Out of the 9 peers that are also analyzing SNDX, 0 agree with Chris's Rating of Hold.

These are the ratings of the 9 analyists that currently disagree with Chris

---

• Joel Beatty of "Baird" Maintained at Buy with Decreased Target to $28 on, Tuesday, October 3rd, 2023
• Edward White of "HC Wainwright & Co." Reiterated at Strong Buy with Increased Target to $42 on, Monday, October 2nd, 2023
• Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $33 on, Wednesday, August 16th, 2023
• George Farmer of "Scotiabank" Initiated at Buy and Held Target at $39 on, Thursday, July 27th, 2023
• Peter Lawson of "Barclays" Maintained at Buy with Increased Target to $34 on, Wednesday, July 26th, 2023
• Yigal Nochomovitz of "Citigroup" Maintained at Strong Buy with Increased Target to $35 on, Wednesday, July 26th, 2023
• Kalpit Patel of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $36 on, Tuesday, July 25th, 2023
• Michael Schmidt of "Guggenheim" Maintained at Strong Buy with Increased Target to $42 on, Tuesday, July 25th, 2023
• Justin Zelin of "BTIG" Maintained at Strong Buy with Increased Target to $35 on, Monday, June 26th, 2023

Contributing Sources

---